ViroGates AS (OCSE:VIRO) Interest Expense: kr-0.65 Mil (TTM As of Mar. 2026)

What is ViroGates AS Interest Expense?

ViroGates AS OCSE:VIRO -1.92% 48 Interest Expense is kr-0.65 Mil as of Mar. 2026. GuruFocus rates OCSE:VIRO with a GF Score™ of 48/100 and a GF Value™ of kr6.74 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. ViroGates AS's interest expense for the three months ended in Mar. 2026 was kr -0.11 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.65 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. ViroGates AS's Operating Income for the three months ended in Mar. 2026 was kr -2.87 Mil. ViroGates AS's Interest Expense for the three months ended in Mar. 2026 was kr -0.11 Mil. ViroGates AS did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

ViroGates AS (OCSE:VIRO) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

ViroGates AS's Interest Expense for the three months ended in Mar. 2026 was kr-0.11 Mil. Its Operating Income for the three months ended in Mar. 2026 was kr-2.87 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was kr3.02 Mil.

ViroGates AS's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

ViroGates AS did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

ViroGates AS Interest Expense Historical Data

* Premium members only.

The historical data trend for ViroGates AS's Interest Expense can be seen below:

ViroGates AS Interest Expense Chart

ViroGates AS Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Interest Expense

Get a 7-Day Free Trial

-0.19

-0.11

-0.57

-0.66

-0.80

ViroGates AS Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Interest Expense	Get a 7-Day Free Trial															-0.26	-0.29	-0.13	-0.12	-0.11

48GF Score

ViroGates AS OCSE:VIRO

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

ViroGates AS Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.65 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of kr-0.65 Mil mean?

ViroGates AS (OCSE:VIRO) has a Interest Expense of kr-0.65 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on ViroGates AS and its competitors.

Is ViroGates AS's Interest Expense too high?

ViroGates AS's current Interest Expense is kr-0.65 Mil. Overall, ViroGates AS has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does ViroGates AS's Interest Expense compare to ABT and SYK?

ViroGates AS's Interest Expense of kr-0.65 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Medical Devices & Instruments company?

A good Interest Expense depends on the Medical Devices & Instruments industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on ViroGates AS and its competitors. ViroGates AS's current Interest Expense is kr-0.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is ViroGates AS stock overvalued right now?

Based on GuruFocus' analysis, ViroGates AS (OCSE:VIRO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr6.74, compared to a current price of kr10.20 — trading 51.3% above its estimated fair value. The current Interest Expense is kr-0.65 Mil. ViroGates AS's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For ViroGates AS (OCSE:VIRO), the current Interest Expense is kr-0.65 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ViroGates AS (OCSE:VIRO) Overvalued in 2026?

Based on GuruFocus' analysis, ViroGates AS stock appears to be overvalued. The current stock price of kr10.20 is trading 51.3% above its estimated GF Value™ of kr6.74. GuruFocus considers ViroGates AS to be Significantly Overvalued.

Key valuation signals for OCSE:VIRO:

Interest Expense: kr-0.65 Mil
GF Value™: kr6.74 vs. price of kr10.20 (51.3% above fair value)
GF Score™: 48/100 with 2 warning signs

No single metric tells the full story. See the OCSE:VIRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ViroGates AS Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies OCSE:SMSMED ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760 STE ZBH XSWX:SOON LSE:SN.PEN SHSE:688271 GMED TSE:7733 PODD

Address Banevaenget 13, Birkerod, DNK, 3460

Website https://www.virogates.com

ViroGates AS is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. The company markets its blood test products under the suPARnostic brand. Its product portfolio comprises suPARnostic TurbiLatex, suPARnostic Quick Triage, and suPARnostic Auto Flex ELISA kit. These products are mainly used to measure the suPAR (soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream.

48GF Score

Get the complete analysis for OCSE:VIRO

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr10.20

Price

kr6.74

GF Value

View OCSE:VIRO Analysis

See Interest Expense data for all stocks →